The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry,
which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK.
The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its
investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout
each module.
A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am.
NPA calls for funding to boost pharmacy resilience
Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health
services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.
Community pharmacies played a central role in the government's response to the Covid-19 pandemic, delivering more than 22 million jabs in the past 12 months.
Besides delivering millions of jabs, latest figures from NHS England and NHS Improvement (NHSE&I) revealed a 50 per cent increase in the number of pharmacies
delivering Covid boosters compared from October 2021 to January 2022.
NHSE&I released the data on Friday (January 14) to thank community pharmacy teams for their work during the crisis time.
Lauding the efforts made by community pharmacy teams during the pandemic, Pharmaceutical Services Negotiating Committee (PSNC) director of NHS Services Alastair Buxton said: "Just over a year ago we were fighting for Government recognition of the part community pharmacy could play in administering Covid vaccines, so a year later it is great to see the efforts of the pharmacy vaccination sites being praised by NHSE&I, with recognition of the significant role they have played in the overall programme.
Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.
The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant
dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable
groups will receive their appointments the week after.
On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18.
The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have
already scheduled Covid vaccinations alongside their flu jabs.
The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These
groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and
individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.
UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir.
The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection.
Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection.
A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent.
It further revealed that Paxlovid is most effective when taken in the early stage of infection.
Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered
intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."
The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry.
The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for
future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge.
The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that
module takes place on Tuesday 28 February.
This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by
the Inquiry of witnesses.
NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure
that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.
British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all
known virus variants.
Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment
available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18).
AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023.
These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune
suppressing treatments. They account for nearly 2% of the global population.
AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio.
The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time
AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.
It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant.
"It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months.
"That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.
Britain will start to roll out Merck's molnupiravir Covid-19 antiviral pill through a drug trial later this month, Susan Hopkins, chief medical adviser at the UK Health Security Agency said on Sunday (November 7).
Last week Britain became the first country in the world to approve the potentially game-changing Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.
The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc.
Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December."
Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.
Deviating from the initial schedule to kick off the flu and Covid-19 vaccination campaigns in October, the NHS England has announced that the autumn
vaccination drive will commence sooner than expected in England, starting on September 11. This decision was taken as a precaution in response to a new Covid-19
variant.
The precautionary measure is being taken as the Department of Health and Social Care and the UK Health Security Agency examined the variant BA.2.86, which was first
detected in the UK on Friday, August 18, 2023, the NHSE said on Aug. 30.
While NHS England had previously announced that vaccinations for both NHS programmes would begin on October 2 for residents of older adult care homes, appointments
for other eligible groups were scheduled for the following week, starting on October 7. This decision prompted community pharmacy leaders to denounce the delayed
start of the flu service as 'unacceptable'.
US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory
illnesses and help improve readiness for any future pandemics.
The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement.
Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris
Johnson to reopen the economy from stringent lockdowns.
Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV).
"By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be
pandemic ready," Bancel said on Wednesday.
As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19
vaccine face termination in just a fortnight.
Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022.
Those who are exempted from taking the vaccination do not fall under this purview.
According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31.
All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period
There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said.
Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid.
The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns.
"Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.
The National Pharmacy Association (NPA) views the COVID vaccination programme as broadly successful, largely due to the efforts of healthcare workers and
volunteers.
However, it cited some areas that could be improved, notably the early involvement of community pharmacies in planning, operational challenges, and recognising
the role of community pharmacy in addressing vaccine hesitancy and inequalities.
Submitting its evidence to the Covid-19 Inquiry, the NPA highlighted that the community pharmacy should have been consulted and involved earlier in the planning
process, considering their two years of experience and expertise in administering annual influenza vaccination programs and the reach and resources of the 14,000
community pharmacies across the UK.
"Instead, community pharmacy was initially given a gap in service role, which failed to fully utilize their experience, expertise and resource," Lawyer Brian
Stanton told the Inquiry on behalf of the NPA during the Module 4 Preliminary Hearing on 22 May.
England won't have any new Covid-19 restrictions before the end of 2021, health secretary Sajid Javid said on Monday (December 27) whilst the government awaits more evidence on whether the NHS can cope with high infection rates in the new year.
"There will be no further measures before the new year," Javid told reporters, adding: "When we get into the new year, of course we will see then whether we do need to take any further measures."
He said that the highly transmissible Omicron variant of the virus now accounted for around 90 per cent of cases across England and urged people to celebrate New Year
cautiously.
The government's attention is focused on the number of patients being hospitalised with Omicron after early data last week suggested the variant carried a lower
risk of admission.
The latest data showed the number of patients in hospital in England with Covid-19 was its highest since March, at 8,474, but a long way off peaks above 34,000 in January.
A combination of factors, including Britain's vaccination programme, the lag between infections and hospitalisations and the potentially less harmful effects of the Omicron variant have all been put forward by health experts as possible explanations for lower numbers.
An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights
for Covid-19 interventions between the pharmaceutical industry and developing nations endures.
At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries
when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected.
In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry
collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA).
The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved
in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck.
The declaration is not legally binding.
However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.
Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva.
"An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and
Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain
regulatory approval in the UK."
In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology.
Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."
UK regulator has approved a new age-appropriate formulation of the Pfizer BioNTech Covid-19 vaccine for use in children aged 5 to 11 years old.
The new paediatric formulation of Covid vaccine meets the required safety, quality and effectiveness standards, the Medicines and Healthcare products Regulatory
Agency (MHRA) announced on Wednesday (December 22).
Dr June Raine, MHRA chief executive said that parents and carers can be reassured that this approval has been given after robust review of safety data.
These data showed a favourable safety profile for use in 5-11-year olds compared with that seen in other age groups, the regulator said.
Raine said: "We have carefully considered all the available data and reached the decision that there is robust evidence to support a positive benefit risk for children in this age group.
Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise.
The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa.
Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England.
Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last.
But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people.
"These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.